Last reviewed · How we verify
Zingiber officinalis
Ginger root contains active compounds (gingerols and shogaols) that inhibit inflammatory mediators and modulate immune responses.
Ginger root contains active compounds (gingerols and shogaols) that inhibit inflammatory mediators and modulate immune responses. Used for Nausea and vomiting (including chemotherapy-induced and post-operative), Osteoarthritis and rheumatoid arthritis, Dyspepsia and gastrointestinal discomfort.
At a glance
| Generic name | Zingiber officinalis |
|---|---|
| Sponsor | Miglani, Anjali |
| Drug class | Herbal/botanical extract |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology, Rheumatology, General wellness |
| Phase | FDA-approved |
Mechanism of action
Zingiber officinalis (ginger) exerts anti-inflammatory effects primarily through inhibition of NF-κB signaling and reduction of pro-inflammatory cytokines such as TNF-α and IL-6. The rhizome also possesses antioxidant properties and may enhance gastrointestinal motility, contributing to its traditional use in nausea and digestive complaints.
Approved indications
- Nausea and vomiting (including chemotherapy-induced and post-operative)
- Osteoarthritis and rheumatoid arthritis
- Dyspepsia and gastrointestinal discomfort
- Migraine prophylaxis
Common side effects
- Gastrointestinal upset (heartburn, abdominal discomfort)
- Allergic reactions (rare)
- Bleeding risk (at high doses, due to antiplatelet effects)
Key clinical trials
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy (PHASE2, PHASE3)
- Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention (NA)
- The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome (PHASE2)
- Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens (NA)
- Efficacy of Zingiber Officinalis (Homoeopathic Medicine) in Treatment of Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zingiber officinalis CI brief — competitive landscape report
- Zingiber officinalis updates RSS · CI watch RSS
- Miglani, Anjali portfolio CI